Explore the latest in dyslipidemia from The JAMA Network, including recent guidelines for screening and use of statins, PCSK9 inhibitors, and other treatments.
This study used a Markov decision model to determine the cost-effectiveness of a PCSK9 inhibitor and statin treatment strategy compared with a statin-alone strategy, using results of the FOURIER trial.
This cohort study determines whether mitochondrial DNA copy number, measured in an easy accessible tissue (buffy coat/circulating leukocytes), is associated with improved risk classification for cardiovascular disease and help guide initiation of statin therapy for primary prevention of cardiovascular disease.
This systematic review and meta-analysis compares the clinical effectiveness of coronary computed tomography angiography with that of functional stress testing for patients with suspected coronary artery disease.
This study examines clinician rationale for ordering monitoring lipid panels among patients on statin therapy and the association of treatment changes with testing.
This study examines PCSK9i cost-sharing requirements for Medicare Part D plans nationwide, which insure 41 million beneficiaries.
This study evaluates the cost-effectiveness of evolocumab in patients with atherosclerotic cardiovascular disease when added to standard background therapy.
This Viewpoint promotes using outcomes-based pricing strategies for proprotein convertase subtilisin/kexin type 9 inhibitors.
This study evaluates patient access to PCSK9 inhibitors among those prescribed therapy.
This mendelian randomization analysis of individual-participant data estimated the association between changes in levels of low-density lipoprotein cholesterol (and other lipoproteins) and risk of cardiovascular events due to CETP variants, alone and in combination with HMGCR variants.
This data analysis simulates the annual price of evolocumab under the outcome-based contracts proposed by Amgen and puts estimates in the context of the available evidence on the cost-effectiveness of PCSK9 inhibitors.
This cohort study assesses the performance of a lifestyle-based risk tool to estimate atherosclerotic cardiovascular disease events over 25 years in adults before 55 years of age.
This population-based study examines the use of and adherence to drugs from classes commonly used for therapy in patients with cardiovascular disease and diabetes.
This simulation model study estimates the percentage of patients with atherosclerotic cardiovascular disease who would require proprotein convertase subtilisin/kexin type 9 inhibitor therapy when oral therapy to lower lipid levels is intensified first.
This Viewpoint summarizes the debate surrounding the LDL hypothesis and suggests next steps for better reducing atherosclerotic cardiovascular disease risk.
This Viewpoint summarizes treatment options for lowering low-density lipoprotein cholesterol levels, specifically the effects of adding additional drugs to statin therapy.